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ABSTRACT 
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Submitted by CHEN Zhang for the degree of Master of Philosophy in Chemical 
Pathology at The Chinese University of Hong Kong in July 2011 
It has been shown that the prenatal diagnosis of fetal trisomy 21 by next generation 
sequencing of DNA molecules in the plasma of pregnant women could be achieved in an 
accurate and noninvasive way. Noninvasive detection of trisomy 13 and 18 is also an 
important clinical application for next generation sequencing. However, whether this 
sequencing approach could also be applied to the noninvasive prenatal diagnosis of 
trisomy 13 and 18 is unclear. To address this question, 392 pregnancies were studied by 
next generation sequencing technology in this thesis, including 25 with a trisomy 13 fetus 
and 37 with a trisomy 18 fetus. 
In the first part of the thesis, the feasibility of noninvasive prenatal diagnosis of trisomy 
13 and 18 was assessed by using the bioinformatics analysis pipeline originally 
developed for trisomy 21 detection. Trisomy 13 could be detected at a sensitivity of 
36.0% and specificity of 92.4%, while the trisomy 18 could be detected at the sensitivity 
of 73.0% and specificity of 97.2%. The results showed that the performance for trisomy 
13 and 18 detection was suboptimal. Further modification of the bioinformatics analysis 
pipeline was needed to improve the performance for trisomy 13 and 18 detection by next 
generation sequencing technology. 
i 
In the second part of the thesis, efforts had been made to improve the bioinformatics 
analysis pipeline for trisomy 13 and 18 detection in three aspects. First, the alignment 
procedure in the analysis pipeline was improved in order to increase the aligned reads. 
Second, the GC content bias had been reduced by two independent methods. The 
precision of quantifying chrl3 and chrl8 and the performance for trisomy 13 and 18 
detection had been greatly improved by these two methods. Third, a new statistical 
approach that compared chromosomes within the sample was developed. Unlike the z 
score approach used in the analysis pipeline for trisomy 21 detection, no control samples 
were needed to detect trisomy 13 and 18. After these improvements, all trisomy 13 cases 
could be detected at a specificity of 98.5%. The trisomy 18 cases could be detected with a 
sensitivity of 94.6% at a specificity of 99.6%. 
In summary, with the improved bioinformatics analysis pipeline, noninvasive prenatal 
diagnosis of trisomy 13 and 18 by maternal plasma DNA sequencing could be achieved 
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SECTION I : BACKGROUND 
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CHAPTER 1: Prenatal diagnosis of fetal trisomy by next generation 
sequencing technology 
1.1 Fetal trisomy 
There are 23 pairs of chromosomes in a normal human genome, including 22 pairs of 
autosomal chromosomes (chromosome 1 to 22) and one pair of sex chromosomes 
(chromosome X and Y). Trisomy is a genetic disorder in which a person has an extra 
copy of a chromosome, besides the two normal copies. The most common human trisomy 
is trisomy 21, trisomy 18 and trisomy 13, in which an extra chromosome 21, 18 or 13 is 
presented in the human genome. The risk of trisomy increased with the age of a pregnant 
woman. The trisomy is associated with severe morbidity and mortality in the fetuses and 
infants (Driscoll et al. 2009). 
Trisomy 21, occurring in 1 in 800 live births, is the most common trisomy in human 
(Driscoll et al. 2009). It is also called Down syndrome, named after John Langdon Down 
who first reported this syndrome in 1959 (Lejeune et al. 1959). Trisomy 21 is associated 
with cognitive disorders, mental retardation, congenital heart disease, muscle hypotonia, 
short stature, facial dysmorphisms and several other anomalies (Epstein et al. 1991). 
Certain abnormalities such as acute myelogenous leukemia and Alzheimer's disease 
occur at higher frequencies in trisomy 21 patients than in the general population (Kondo 
et al. 2001; Oka et al. 2007; Schupfet al. 2010; Wan et al. 1999). It has been known that 
the abnormal phenotypes are due to an extra copy of chromosome 21. However, the 
molecular mechanisms are still poorly understood (Ait Yahya-Graison et al. 2007; 
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Megarbane et al. 2009). The median survival age of patients with trisomy 21 is 49 years 
(Yang et al. 2002). Nowadays, many efforts have been put to improve the quality of life 
and life expectancy of individuals with trisomy 21, but there is still no effective treatment 
to cure this syndrome (Megarbane et al. 2009). 
Trisomy 13 and trisomy 18 occur in about 1/10,000 and 1/6,000 live births, respectively 
(Driscoll et al. 2009). Trisomy 13 is also called Patau syndrome and was reported by 
Klaus Patau in 1960 (Patau et al. 1960). Trisomy 18 or Edwards syndrome was reported 
by John Hilton Edwards (Edwards et al. 1960). These syndromes are mainly caused by an 
extra chromosome 13 or 18. But other abnormal changes in chromosome 13 or 18, such 
as translocation, are also classified as Patau syndrome or Edwards syndrome. Infants with 
Patau syndrome suffer from serious physical and mental abnormalities, such as heart 
defects and mental retardation (Driscoll et al. 2009). While infants with Edwards 
syndrome show heart defects, kidney abnormalities and severe developmental delays 
(Driscoll et al. 2009). It has been reported that the women with trisomy 13 or trisomy 18 
fetus have high fetal loss rates (Hook et al. 1989). The median survival age for infants 
with Patau syndrome and Edwards syndrome is only 7 days and 14.5 days, respectively. 
However 5% to 10% of patients with trisomy 13 or 18 could survive beyond 12 months 
(Rasmussen et al. 2003). 
1.2 Conventional prenatal diagnosis of fetal trisomies 
Since there is no effective treatment for fetal trisomies, it is important to detect such fetal 
trisomies by prenatal diagnosis. The American College of Obstetricians and 
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Gynecologists (ACOG) has recommended that all pregnant women should be offer 
prenatal screening for trisomies regardless of maternal age or other risk factors (ACOG 
2007). 
Conventional definitive prenatal diagnosis of trisomies is through sampling of fetal 
genetic materials by amniocentesis or chorionic villus sampling (CVS). A small piece of 
chorionic villi or a small amount of amniotic fluid, which normally contains the genetic 
and biochemical information from the fetus, is taken from the pregnant women and 
analyzed. Any chromosomal abnormality could be diagnosed in this way. However these 
approaches are invasive and might result in a risk of fetal miscarriage of around 1% 
(Mennuti et al. 2003; Tabor et al. 1986). This is the major concern of the couples for the 
invasive prenatal diagnosis. 
Due to this reason, many noninvasive screening approaches were also developed by using 
ultrasound scanning and maternal serum makers. For example, pregnancy-associated 
plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (beta-HCG), are 
used as the biomarkers for trisomy 21 detection (Wald et al. 1988). Women with trisomy 
21 fetuses will have lower amounts of PAPP-A but higher amounts of HCG than women 
with normal fetus. Women with trisomy 18 fetuses will have decreased amounts of both 
of these proteins. Besides, ultrasound was used to measure nuchal translucency and the 
nasal bone of the fetus (Nicolaides et al. 1992). However, these approaches measure the 
epiphenomena related to the trisomies, rather than directly detecting trisomic 
chromosomes. Therefore, these approaches have suboptimal sensitivity and specificity 
(Malone et al. 2005; Wapner et al. 2003). 
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1.3 Cell free fetal DNA and its application in prenatal diagnosis 
It has been found that tumour derived DNA could be detected in the plasma or serum of 
cancer patients (Chen et al. 1996; Nawroz et al. 1996; Stroun et al. 1989). In 1997, cell-
free fetal DNA was also found to be present in the plasma and serum of pregnant women 
(Lo et al. 1997). This discovery has provided a new avenue for noninvasive prenatal 
diagnosis (Lo et al. 1998b). Cell-free fetal DNA has been used for the noninvasive 
prenatal diagnosis of fetal rhesus D incompatibility (Finning et al. 2002; Lo et al. 1998a) 
and sex-linked diseases (Finning et al. 2008; Rijnders et al. 2001; Wright et al. 2009). For 
example, by combining the single-nucleotide polymorphism (SN?) information and 
mRNA expression data from chromosome 18 or 21, Lo et al. have developed an approach 
to detect trisomy 18 or 21 noninvasively based on cell free fetal DNA (Lo et al. 2007b; 
Tsui et al. 2009). By analysis of fetal nucleic acids in maternal plasma, the fetal DNA 
methylation signatures were also used for noninvasive prenatal diagnosis of trisomies 
(Tong et al. 2006; Tong et al. 2009). Other techniques such as digital PCR were also 
adapted for the noninvasive detection of fetal trisomies by determining the allelic 
imbalance of specific SNPs in plasma cell-free DNA (Lo et al. 2007a). 
1.4 Next generation sequencing technology 
DNA sequencing technology allows analysis of DNA molecules at a single nucleotide 
level. Such technology has been widely applied to biological research and clinical 
diagnosis. Recently, new sequencing technology which could sequence millions of DNA 
molecules in a parallel fashion with high throughput and low costs were quickly 
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developed. Compared to the early sequencing technologies, those new sequencing 
technologies are therefore referred to as the second-generation sequencing or next-
generation sequencing (NGS) technologies. Among those NGS technologies, 
Illumina/Solexa is currently the most commonly used NGS platform. 
The technique used in the Illumina/Solexa sequencing platform was first developed by 
Turcatti and colleages (Fedurco et al. 2006; Turcatti et al. 2008) and commercialised by 
Solexa which was later acquired by Illumina. The basic principle of Solexa sequencing is 
illustrated in Figure 1.1. The DNA templates are linked to specific adapter sequences and 
immobilized on a proprietary flow cell surface. The DNA templates are then amplified by 
bridge PCR (Fedurco et al. 2006). During this process, each DNA template is amplified 
into one cluster containing thousands of identical amplicons in a close proximal physical 
location. Millions of clusters are amplified at the same time. After the bridge PCR 
amplification, the DNA templates are then sequenced based on the sequence-by-synthesis 
(SBS) technique. Four reversible terminator dNTPs with different fluorescent labels are 
added in each sequencing cycle. In each cycle, the correct nucleotide is incorporated into 
the nucleotide acid chain by the polymerase. The fluorescence signal is then detected by a 
CCD camera in four channels corresponding to the nucleotide A, T, C or G, respectively. 
The terminator group of dNTP and fluorescent label are then removed followed by a new 
sequencing cycle. The sequences of DNA molecule could be determined by repeating the 
sequencing cycle. Millions of clusters could be simultaneously sequenced in parallel, 
resulting in a very high sequencing throughput. Furthermore, the flow cell contains eight 
sequencing lanes so that multiple samples could be sequenced at the same time, which 
therefore further increased the sequencing throughput. 
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The Illumina/Solexa sequencing platform incorporated the multiplex sequencing 
technique. A unique index sequence is added to the sample and it could be read out 
during the downstream analysis. By using this technique, samples could be pooled 
together and sequenced. Therefore, up to 12 samples per lane or 96 samples per flow cell 
could be sequenced simultaneously. The Illumina/Solexa sequencing platform could 
perform single-end or paired-end sequencing, which sequences one or both ends, 
respectively, of the DNA molecules. 
Currently, the Solexa Genome Analyzer IIx could generate around 6.5 Gb sequencing 
data per day and up to 320 million reads with read length from 35 to 150 bp. The most 
advanced Illumina HiSeq 2000 sequencer could generate as much as 25 Gb sequencing 
data per day and one billion sequenced reads per run. 
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Figure 1.1 Illumina/Solexa sequencing platform 
(A) DNA templates are ligated with specific adapters and (B) are allowed to bind to the 
surface of the flow cell. (C) Single stranded DNA templates are amplified by bridge PCR 
into (D) double stranded DNA. (E) The double stranded DNA is then denatured and a 
cluster of amplicons amplified from the same DNA template are generated. (F) Several 
million clusters are generated in distinguishable physical locations. (G) The sequencing-
by-synthesis process begins by adding four labeled reversible terminators, primers, and 
DNA polymerase. (H) The fluorescence of incorporated nucleotide from each cluster is 
captured by a CCD camera and the sequenced base is determined. (Figure adapted from 
http://www.illumina.com/) 
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1.5 Substantial bias in the next generation sequencing platform 
Many efforts have been made to characterize the biases inherent in NGS technologies. 
One of the major bias that has been reported is called the "G+C content" bias (GC bias) 
(Harismendy et al. 2009). It has been found that the sequenced reads are not uniquely 
distributed across the sequenced regions. This non-uniform sequence coverage appears to 
correlate with the base composition of the sequenced regions. For example, the 
Illumina/Solexa sequencing platform has low coverage in the GC-poor regions and high 
coverage in the GC-rich regions. The read coverage increased with the increased GC 
content (Dohm et al. 2008; Harismendy et al. 2009; Kozarewa et al. 2009). Dohm et al. 
reported that the regions with a GC content of 40% contains almost twice as many reads 
as regions with a 30% GC (Dohm et al. 2008). This is probably due to the PGR steps such 
as the emulsion PCR or bridge PCR in these sequencing technologies (Aird et al. 2011; 
Harismendy et al. 2009). 
It has also been reported that repetitive sequences were overrepresented or 
underrepresented in the sequencing data (Harismendy et al. 2009). For example, 
Harismendy et al. reported that there was an overrepresentation of repetitive elements in 
the Illumina/Solexa sequencing platform. 
Another bias in the NGS technologies is duplicate sequences in which the sequenced 
reads have the exactly the same start and end positions. These duplicate sequences are 
possibly the result of PCR amplification, adaptor dimers and sequencing artifacts 
(Kozarewa et al. 2009). 
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These biases might affect the application of the NGS technologies such as single 
nucleotide polymorphisms detection and de novo assembly. These biases should be 
carefully assessed and addressed when applying such technologies. 
1.6 Prenatal diagnosis of trisomy by next generation sequencing 
Theoretically, if a woman is pregnant with a trisomy fetus, there should be an 
overpresentation of the fetal-derived DNA from the trisomic chromosome in the maternal 
plasma, when compared to a woman pregnant with a euploid fetus. This overpresentation 
could be detected by the DNA sequencing techniques. Chiu et al. applied NGS 
technology of noninvasive prenatal diagnosis of trisomy 21 (Chiu et al. 2008; Chiu et al. 
2010). All the trisomy 21 and euploid cases could be correctly identified in this study. In 
2011, Chiu et al. further validated this approach on a large scale study with 753 pregnant 
women by using multiplex sequencing protocols. The trisomy 21 fetuses were detected at 
100% sensitivity and 97.9% specificity by using the 2-plex sequencing protocol (Chiu et 
al. 2011). 
Fan et al. also developed a similar approach based on NGS technology for noninvasive 
prenatal diagnosis of trisomies (Fan et al. 2008; Fan et al. 2010). However, their sample 
size was relatively small and included 9 trisomy 21, 2 trisomy 18, and 1 trisomy 13 cases. 
Besides, the samples were all collected after amniocentesis or CVS. This procedure has 
been shown to contribute to the increase of fetal DNA concentration in maternal blood 
(Samura et al. 2003). Therefore the diagnostic accuracies of their study could not be 
conclusively ascertained, especially for trisomy 13 and 18 detection. 
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Therefore, whether the NGS technology could be applied for noninvasive prenatal 
diagnosis of trisomy 13 and 18 is unclear. 
1.7 Aims of this thesis 
This thesis aims to assess the feasibility of noninvasive prenatal diagnosis of trisomy 13 
and 18 by next generation sequencing of plasma DNA. The aim of the thesis also 
includes the development and improvement of the bioinformatics analysis pipeline for the 
trisomy 13 and 18 detection. 
The first part of the thesis investigated the feasibility of noninvasive prenatal diagnosis of 
trisomy 13 and 18 by using the bioinformatics analysis pipeline originally developed for 
trisomy 21 detection (Chapter 3). 
The second part of the thesis improved the bioinformatics analysis pipeline for trisomy 13 
and 18 detection in three aspects. First, the alignment procedure in the analysis pipeline 
was improved in order to increase the number of aligned reads (Chapter 4). Second, the 
GC content bias had been reduced by two independent methods (Chapters 5-6). The 
precision of quantifying chrl3 and 18 and the performance for trisomy 13 and 18 
detection had been greatly improved by these two methods. Third, a new statistical 
approach that compared the chromosomes within the sample was developed (Chapter 7). 
Unlike the z score approach used in the analysis pipeline for trisomy 21 detection, no 
control samples were needed to detect the trisomy 13 and 18 in the new statistical 
approach. 
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In Chapter 8, a general conclusion of the study in this thesis will be made. The future 
perspectives of the trisomy 13 and 18 detection will also be discussed. 
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CHAPTER 2: Methods for noninvasive prenatal diagnosis of fetal 
trisomy maternal plasma DNA sequencing 
2.1 Study design and participants 
2.1.1 Ethics Statement 
All participants involved in this thesis gave informed written consent. Ethics approvals 
were obtained from the institutional review boards of each recruitment site. 
2.1.2 Study design, setting and participants 
A total of 392 participants were involved in this thesis. Among them, 252 participants 
were recruited prospectively from Hong Kong, the Netherlands and the United Kingdom. 
The remaining 140 archived maternal plasma samples from pregnancies were retrieved 
from the participating sites in the Netherlands and the United Kingdom. A series of 
inclusion criteria from the previous study on the prenatal diagnosis of trisomy 21 has 
been used in the recruitment (Chiu et al. 2011). Only singleton pregnancies with clinical 
indications for CVS or amniocentesis were recruited. Samples without full karyotyping 
results were filtered out. 
A total of 392 cases, including 25 trisomy 13 cases, 37 trisomy 18 cases and 86 trisomy 
21 cases were analyzed in this thesis. 314 of the cases were from a study on the 
noninvasive diagnosis of trisomy 21 with a 2-plex sequencing strategy (Chiu et al. 2011). 
30 cases were also from this study with a 8-plex sequencing strategy (Chiu et al. 2011), 
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but were re-sequenced with 2-plex sequencing in this study. The remaining 48 cases were 
newly recruited. 
Amongst these 392 pregnancies, 243 were pregnancies with euploid fetuses (Figure 2.1). 
103 of these euploid samples were used as reference controls for the following z score 
statistical analysis. Amongst these euploid control samples, 13 were used in two flow 
cells (sequenced twice) and the remaining 90 cases were used in only one flow cell. 
To fully investigate the sensitivity and specificity for trisomy 13 detection, the 25 trisomy 
13 cases were compared with the 264 non-trisomy 13 cases (including 140 euploid cases 
not used as reference controls, 86 trisomy 21 cases, 1 sex chromosome mosaic case and 
37 trisomy 18 cases). Similarly, 37 trisomy 18 cases were compared with 252 non-
trisomy 18 cases (including 140 euploid cases not used as reference controls, 86 trisomy 
21 cases, 1 sex chromosome mosaic case and 25 trisomy 13 cases). Diagnostic 
performance was assessed by comparing with the full karyotyping results from the 
amniotic fluid or CVS. 
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and non-trisomy 18 
Figure 2.1 Sample recruitment 
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2.2 Maternal plasma DNA sequencing 
Plasma DNA from participating pregnant women were prepared and sequenced as 
previously described (Chiu et al. 2011; Chiu et al. 2008). All plasma samples were 
collected before amniocentesis or CVS. 
In summary, the plasma DNA was extracted by the double centrifugation protocol (Chiu 
et al. 2001). The DNA library for the extracted plasma DNA was according to 
manufacturer's instructions. Since the multiplexing sequencing strategy was incorporated 
in the sequencing, a 6-bp index sequence was added to the adapter-ligated DNA of each 
plasma sample. Indexed DNA libraries were sequenced with the 2-plex sequencing 
strategy (Chiu et al. 2011). The 2-plex multiplexing strategy allows two plasma samples 
to be sequenced in the same sequencing lane. These two samples could be distinguished 
by two different short index sequences (6 bp) for each sample. The index sequences were 
randomly assigned to the sequencing samples. There are eight sequencing lanes in each 
sequencing run so that a total of 16 samples could be sequenced in each run. The 36 
basepairs (bp) from one end of each plasma DNA molecule were sequenced. An 
additional 7 sequencing cycles were performed to obtain the index sequence on each 
DNA molecule. 
In each sequencing run, four male euploid samples were sequenced as reference control 
samples. The remaining samples in the same sequencing run were test samples. Trisomy 
samples were detected by comparing the test samples with control samples within each 
sequencing run by a specific statistical approach. 
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2.3 Sequencing data analysis 
The original bioinformatics analysis pipeline was developed for trisomy 21 detection 
(Chiu et al. 2008). This analysis pipeline will be evaluated and further improved for 
trisomy 13 and 18 detection in the following chapters. Therefore, all the study in the 
thesis was based on this bioinformatics analysis pipeline. Modification of the analysis 
pipeline and development of other algorithms for trisomy 13 and 18 detection will be 
specified in the methods part of related chapters. The analysis pipeline for trisomy 21 
detection mainly contains following three steps (Figure 2.2): 
Read alisnment 
In order to obtain the location of sequenced reads in the genome, all the raw reads were 
aligned to a repeat-masked genome (NCBI Build 36 version 48) without any mismatch 
allowable. Those reads mapping to multiple locations were filtered for further analysis. 
Only the uniquely aligned reads were retained. Due to the 2-plex sequencing strategy, the 
reads from two different samples in the same lane were sorted back to each other 
according to the index DNA sequence information without any mismatch allowable. 
Chromosome quantification 
The number of uniquely aligned reads for each chromosome was counted. The percentage 
of the reads originated from each chromosome over total reads was calculated, termed 
genomic representation (GR). 
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Trisomy detection 
The z score approach for trisomy detection was developed by Chiu et al (Chiu et al. 2011; 
Chiu et al. 2008), named the standard z-score approach. When compared with the euploid 
reference samples, the maternal plasma sample from a pregnancy with a trisomy 13 or 18 
fetus is expected to have a higher genomic representation of chrl3 or chrl8. In order to 
measure this overrepresentation, the z-score for the chromosome of interest (chrl3 or 
chrl8) was calculated by the following equation: 
z-score test sample 一 (GR test sample _ GR mean reference samples)/SD reference samples 
Where GR test sample is the genomic representation of the chromosome of interest in the test 
sample; GR mean reference samples IS the mean of the genomic representations of the 
chromosome of interest for all reference samples; and SD reference samples is the standard 
deviation of the genomic representation of the chromosome of interest for the reference 
samples. 
The z-score value 3 was used as the cutoff to classify the fetal trisomy 13 orl8. A z-score 
value greater than 3 indicated the genomic representation of chrl3 or chrl8 is greater 
than that of the 99.9& percentile of the reference set for a one-tailed distribution and thus 
the overrepresentation of chrl3 or chrl 8 plasma DNA molecules were presented. 
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TGCTAGCTAGCTACGA •••... Chr4 
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Figure 2.2 Noninvasive prenatal diagnosis of trisomy by next generation sequencing 
technology 
(A) The sequenced reads from plasma DNA molecules were aligned to the human 
reference genome with repeat sequences masked. (B) The uniquely aligned reads of each 
chromosome were counted. The percentage of unique reads mapped to each chromosome 
was calculated as the genomic representation. (C) The z score statistics was calculated by 
comparing the result from a test sample with that from the control euploid samples. 
Samples with z score > 3 were classified as trisomic samples. Otherwise, a sample was 
classified as a euploid sample. 
20 
SECTION III: TRISOMY 13 AND 18 DETECTION BY 
THE T21 BIOINFORMATICS ANALYSIS PIPELINE 
21 
The T21 bioinformatics analysis pipeline for trisomy 13 and 18 detection 
CHAPTER 3: The T21 bioinformatics analysis pipeline for trisomy 
13 and 18 detection 
3.1 Introduction 
Recently, NGS technologies have been applied to noninvasive diagnosis of trisomy 21 by 
sequencing the maternal plasma DNA (Chiu et al. 2011; Chiu et al. 2008; Chiu et al. 
2010; Fan et al. 2008; Fan et al. 2010). Our group has developed a bioinformatics 
analysis pipeline for trisomy 21 detection based on NGS (Chiu et al. 2008) (thereafter this 
pipeline is referred to as the "T21 bioinformatics analysis pipeline"). By using this 
analysis pipeline, the trisomy 21 could be detected at a sensitivity of 100% and specificity 
of 98% (Chiu et al. 2011). However, whether this analysis pipeline could be applied 
directly to trisomy 13 and 18 detection by NGS is unclear. 
In this chapter, I will assess the performance of the T21 bioinformatics analysis pipeline 
for trisomy 13 and 18 detection by NGS. 
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3.2 Methods 
3.2.1 T21 bioinformatics analysis pipeline for trisomy 13 and 18 detection 
The T21 bioinformatics analysis pipeline was tested for trisomy 13 and 18 detection. The 
sequenced reads (36 bp) were aligned to the repeat masked reference human genome by 
the Short Oligonucleotide Alignment Program 2 (S0AP2) (Li et al. 2009) with no 
mismatch allowable. The reads mapped to multiple locations were filtered for the 
following analysis and only uniquely aligned reads were retained. Due to the 2-plex 
strategy, reads from different samples in the same sequencing lane were sorted back to 
the corresponding samples according to their short index sequences. No mismatch was 
allowed in the index sequences. 
The genomic representation of chrl3 or chrl8 was calculated as the percentage of the 
reads originated from chrl3 or chrl8 over total reads. The z score was calculated as 
described in Chapter 2. The Wilcoxon Rank Sum was used to compare the difference 
between the two groups. 
3.3 Results 
3.3.1 Performance of the T21 bioinformatics analysis pipeline for trisomy 13 and 
18 detection 
Theoretically, there should be an overrepresentation of trisomic chromosome in the 
trisomy samples compared to the non-trisomy samples. Therefore, the genomic 
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representation of trisomic chromosome from the trisomy samples should be greater than 
that for the non-trisomy samples. Furthermore, in an ideal situation, it would be expected 
that the genomic representation of trisomic chromosome would clearly separate the 
trisomy samples from non-trisomy samples. To test this, the genomic representation of 
chr 13 and chr 18 was calculated and plotted in Figure 3.1 A and Figure 3.2A. The genomic 
representation of chr 13 from the trisomy 13 samples (mean = 3.34%) was higher than 
that from non-trisomy 13 samples (mean = 3.25%) (p value = 0.0029). Similarly, the 
genomic representation of chr 18 from trisomy 18 samples (mean = 2.83%) was also 
higher than that from non-trisomy 18 samples (mean = 2.95%) (p value < 2.2 x 10'^^). 
This indicated that there was an overrepresentation of chr 13 or chr 18 in trisomy 13 or 18 
samples compared with the non-trisomy samples. However there was an overlap between 
the genomic representation of chr 13 or chr 18 between the trisomy and non-trisomy 
samples. Therefore those overlapped samples could not be classified correctly. 
The z scores of chr 13 and chr 18 were then calculated (Figure 3. IB and Figure 3.2B). By 
using a cutoff of z score value 3, 9 out of 25 trisomy 13 and 242out of 264 non-trisomy 
13 cases could be correctly identified, resulting in a sensitivity of 36.0% and specificity 
of 91.7%. For trisomy 18 detection, 28 out of 37 trisomy 18 and 244 out of 252 non-
trisomy 18 cases could be correctly identified. The sensitivity and specificity were 75.7% 
and 96.8%, respectively. These results indicated that the performance of the T21 
bioinformatics analysis pipeline was suboptimal for trisomy 13 and 18 detection by NGS 
when compared with the trisomy 21 detection. 
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Figure 3.1 Trisomy 13 detection by the T21 bioinformatics analysis pipeline 
(A) The genomic representation of chrl3 for the trisomy 13, non-trisomy 13 and control 
samples (B) The z score of chrl3 for the trisomy 13, non-trisomy 13 and control samples. 
Dashed line indicated the diagnostic cutoff with a z score value of 3. T13, trisomy 13. 
GR, genomic representation. 
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Figure 3.2 Trisomy 18 detection by the T21 bioinformatics analysis pipeline 
(A) The genomic representation of chrl 8 for the trisomy 18, non-trisomy 18 and control 
samples (B) The z score of chrl 8 for the trisomy 18, non-trisomy 18 and control samples. 
Dashed line indicated the diagnostic cutoff with a z score value of 3. T18, trisomy 18. 
GR, genomic representation. 
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3.3.2 The precision of quantifying chrl3 and chrl8. 
The performance of the T21 bioinformatics analysis pipeline on the detection of trisomy 
13 and 18 was suboptimal when compared with trisomy 21 detection. It was probably due 
to the imprecision of quantifying chrl 3 and chrl 8 compared with chr21. To test this, the 
coefficient of variation (CV) of measuring the GR of autosomes among the euploid 
control samples was calculated. As shown in Figure 3.3, the CVs of quantifying chrl 3 
and chrl 8 were 1.52% and 0.83%, respectively. They were greater than the CV of 
quantifying chr21, which is 0.62%. This result indicated that chrl3 and chrl8 was less 
precisely measured than chr21 by NGS. 
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Figure 3.3 The precision of quantifying autosomes based on the T21 bioinformatics 
analysis pipeline. 
CVs for each autosomes was calculated based on the control euploid cases within each 
sequencing run. Chromosomes were ordered from left to right in increasing GC contents. 
95% confidence interval was shown in error bars. 
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3.4 Discussion 
In this chapter, the performance of the T21 bioinformatics pipeline for trisomy 13 and 18 
detection was assessed based on a large series of trisomy 13 an 18 cases. The detection 
rate of this analysis pipeline for trisomy 13 and 18 detection was 36.0% and 75.7%, 
which was much worse than that for trisomy 21 detection. The performance difference 
was due to the less precise measurement of chrl3 and chrl8 than chr21 by NGS. 
This suboptimal performance of the T21 bioinformatics analysis pipeline for trisomy 13 
and 18 detection indicated that further improvement of this analysis pipeline was needed. 
The T21 bioinformatics analysis pipeline mainly contained three steps. Therefore, in the 
following section, efforts will be made to improve the three steps in this analysis pipeline 
one by one, which are read alignment, quantification of chromosomes and the statistical 
analysis for trisomy detection. 
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CHAPTER 4: Improving the alignment 
4.1 Introduction 
The first step of the T21 bioinformatics analysis pipeline was the read alignment. Efforts 
will first be made to improve this step. 
It has been reported that to increase the number of sequenced reads would improve the 
detection accuracy for trisomy 21 due to the improved precision of measuring chr21 in 
the plasma sequencing data (Chiu et al. 2011). This might also be applicable to the 
improvement of the trisomy 13 and 18 detection, but still needs to be tested. However 
increasing the number of sequenced reads would also increase the sequencing cost (Chiu 
et al. 2011). An alternative way was to improve the alignment in the bioinformatics 
analysis procedure, so that more aligned reads could be obtained. To achieve this goal, 
several possible solutions could be considered. 
First, we could allow mismatches in the index sequences when sorting back the reads into 
corresponding samples. In the T21 analysis pipeline, no mismatch was allowed in the 
index sequences. However, due to the sequencing error and other potential problems in 
the sample preparation process, it was possible that the index sequences that had been 
sequenced might not be exactly the same as those we originally designed. Consequently, 
those reads with the unmatched index sequence could not be sorted back to its 
corresponding sample. Whether this could improve the trisomy detection needs further 
investigation. 
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Second, we could use a non-masked human reference genome instead of a repeat masked 
one as the alignment reference. In the repeat masked reference genome, the repetitive 
sequences were masked and thus these regions were excluded for alignment. In order to 
exclude the reads from the repeat regions, which might have multiple alignments, the 
repeat masked genome was adapted as an alignment reference in the T21 analysis 
pipeline. However, whether these reads from the repetitive regions could actually be 
uniquely aligned back needs further study. 
Third, we could allow mismatches in the read alignment. In the previous analysis, only 
the perfectly aligned reads were retained. Similarly, due to sequencing error and the 
presence of polymorphisms in the human genome, the sequenced reads might not be 
exactly the same as its corresponding reference genomic sequences (Dohm et al. 2008). 
Allowing mismatch in the read alignment was thus a possible way to increase the aligned 
reads. 
In this chapter, I will investigate whether the above methods could increase the aligned 
reads and further improve the performance of T21 bioinformatics analysis pipeline for 
trisomy 13 and 18 detection. 
4.2 Methods 
4.2.1 Allowing mismatches in the index sequences 
A total of 12 index sequences were provided by Illumina for multiplex sequencing. These 
index sequences were used in plasma DNA sequencing with 2-plex sequencing strategy 
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in this study. Two samples were sequenced in the same sequencing lane and each of them 
was assigned one of the index sequences. During the sequencing process, the index 
sequences would also be sequenced. After sequencing, the reads from the two samples in 
the same lane were mixed together and would be sorted back to the corresponding 
samples according the index sequences. 
The mismatch of the index sequence was defined as the different nucleotides between the 
sequenced one and originally designed one. The maximum mismatches in the index 
sequence was defined as the maximum different nucleotides allowable with which one 
index sequence was still different from all the other ones. To find the maximum 
mismatches allowable in one index sequence, all the possible sequences with 0,1,2. ..n 
mismatches were enumerated and compared with all the other index sequences, until one 
of the possible sequences was the same as one of the other index. 
4.2.2 Calculating the mappability of the human reference genome 
In order to study whether the reads from repetitive regions of the human reference 
genome could be uniquely aligned, a simulation was performed on the non-repeat masked 
human reference genome (Hgl8 NCBI.36). The non-repeat masked human reference 
genome was divided into N-bp simulated reads with 1-bp shift. N was 36, 50 or 75 which 
was the most common read length generated from the Illumina sequencing platform. 
Those simulated reads were then aligned back to the non-repeat masked human reference 
genome with no mismatch allowable by S0AP2 (Li et al. 2009). If a simulated read could 
be uniquely aligned back to the reference genome, it would be retained and the start 
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position of the simulation read would be defined as mappable. The mappability of a 
particular region was then defined as the percentage of mappable nucleotides over the 
total nucleotides in this region. The 'N' nucleotides in the non-repeat masked human 
reference genome were excluded in the analysis. 
4.2.3 Aligning reads to the non-repeat masked human reference genome 
A non-repeat masked human reference genome (Hgl8 NCBL36) instead of the repeat 
masked one was tested as the alignment reference. Reads were aligned by S0AP2 (Li et 
al. 2009). A maximum of 0, 1 and 2 mismatches allowable in the read alignment were 
also tested. 
4.2.4 Trisomy 13 and 18 detection 
The chromosomes were quantified by calculating the genomic representation. The 
trisomy 13 and 18 was detected by calculating the z score as previously described in 
Chapter 2. 
4.3 Results 
4.3.1 Increasing read numbers by allowing mismatches in the index sequences 
One possible way to increase the uniquely aligned reads was to allow mismatches in the 
index sequences when sorting reads back to the corresponding samples. I first checked 
the maximum mismatches allowable in one index sequence with which it could still be 
distinguishable (Table 4.1). For all the index sequences, at least 2 mismatches could be 
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allowed. A more stringent criterion which allowed only 1 mismatch was used in the 
following analysis. 
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Index number Index sequence Maximum mismatches allowable 
1 ATCACG 3 
2 CGATGT 3 
3 TTAGGC 3 
4 TGACCA 3 
5 ACAGTG 3 
6 GCCAAT 2 
7 CAGATC 2 
8 ACTTGA 3 
9 GATCAG 3 
10 TAGCTT 2 
11 GGCTAC 2 
12 CTTGTA 3 
* The maximum mismatches in the index sequence was defined as the maximum 
different nucleotides allowable in the sequence with which one index sequence was still 
different from all the other ones. 
Table 4.1 The maximum mismatches allowable in the index sequences 
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Without mismatch allowable in the index sequences, an average of 2.3 million (SD 
517,888) uniquely aligned reads per sample was obtained (Figure 4.1 and Table 4.4). 
Three samples had relatively low uniquely aligned reads (less than one million). The 
average sequencing coverage was 2.7% (SD 0.61%) per sample. 
The sequencing data were then re-analyzed by allowing one mismatch in the index 
sequences. The average number of uniquely aligned reads for each sample was 2.4 
million (SD 508,842). The average percentage of increase was 6.0% (SD 21.7%) 
compared to the analysis when no mismatch was allowed in the index sequences. After 
allowing one mismatch in the index sequences, the read number of 12 samples increased 
more than 50%. Among these samples, three samples with less than 1 million aligned 
reads in the previous analysis had more than 2 million reads after allowing one mismatch. 
Next, the CVs for quantifying the autosomes were calculated based on the analysis with 1 
mismatch allowable in the index (Figure 4.2 and Table 4.5). For chrl3, the CVs slightly 
increased from 15.2% to 15.3%. For chrl8, the CVs also increased from 8.31% to 8.60%. 
Although the CVs of quantifying autosomes was slightly worse, considering the increase 
in read numbers, especially for those samples with possible errors in the sequenced index 
sequence, 1 mismatch allowable in the index sequence was used in the following 
analysis. 
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4.3.2 Increasing read numbers by using the non-masked reference genome for 
alignment 
Another possible solution for increasing the read number was to use the non-repeat 
masked reference genome instead of the repeat masked one for alignment. 
Before testing the alignment on the non-repeat masked reference genome, I first checked 
whether the reads from the repeat regions could be uniquely aligned by the simulation 
study. As showed in Table 4.2, around 48.8% of the human reference genome was repeat 
sequences. Those sequences were masked in the repeat masked human reference genome. 
If the repeat masked genome was used as alignment reference, reads from these regions 
could not be aligned back and thus would be excluded for further analysis. However, by 
computer simulation with the 36 bp simulated reads, 77.4% of the repeat regions could 
actually be uniquely aligned. The unique alignment rate of the repeat regions increased to 
86.7% and 93.4% with the 50 bp and 75 bp simulated reads, respectively (Table 4.3). For 
the non-repeat regions, around 96.3%, 96.8% and 97.4% could be uniquely aligned with 
36 bp, 50 bp and 75 bp simulated reads, respectively. This indicated that increasing the 
sequenced read length would help increase the unique alignment rate, especially for the 
repeat regions. 
Next, the raw sequencing reads from all the samples were re-aligned to the non-repeat 
masked human reference genome. After sorting back the reads into the corresponding 
samples with one mismatch allowable, average 4.6 million (SD 964,095) of uniquely 
aligned reads per sample were obtained (Figure 4.1 and Table 4.4). The uniquely aligned 
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reads increase by 89% compared to the alignment with the repeat masked genome. As 
shown in Figure 4.2 and Table 4.5, the precision of measuring the autosomes was 
improved. Particularly, for chr 13, the CVs decreased from 1.53% to 1.12%. Similarly, the 
CVs for chr 18 also decreased from 0.86% to 0.67%. This indicated that the precision of 
measuring chr 13 and chr 18 had been improved after using the non-repeat masked human 
genome as the alignment reference. Therefore, this alignment criterion would be adapted 
in the following analysis. 
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Chromosome informative region Non-repeat sequences Repeat sequences 
(million bp) (million bp) (million bp) 
^ 225.0 n 5 3 51.2% 109.7 48.8% 
chr2 237.7 127.5 53.6% 110.2 46.4% 
chr3 194.7 101.0 51.8% 93.8 48.2% 
chr4 187.3 95.6 51.0% 91.7 49.0% 
chr5 177.7 92.2 51.9% 85.5 48.1% 
chr6 167.3 88.2 52.7% 79.1 47.3% 
chr7 155.0 80.3 51.8% 74.7 48.2% 
chr8 142.6 73.7 51.6% 69.0 48.4% 
chr9 120.1 61.9 51.5% 58.2 48.5% 
chrlO 131.6 70.0 53.2% 61.6 46.8% 
chrl l 131.1 66.8 50.9% 64.3 49.1% 
chrl2 130.3 65.5 50.3% 64.8 49.7% 
chrl3 95.6 51.7 54.1% 43.9 45.9% 
chrl4 88.3 45.8 51.8% 42.5 48.2% 
chrl5 81.3 42.9 52.8% 38.4 47.2% 
chrl6 78.9 40.2 51.0% 38.7 49.0% 
chrl7 77.8 40.8 52.5% 37.0 47.5% 
chrl8 74.7 41.0 55.0% 33.6 45.0% 
chrl9 55.8 24.1 43.1% 31.7 56.9% 
chr20 59.5 30.5 51.2% 29.0 48.8% 
chr21 34.2 18.4 53.9% 15.8 46.1% 
chr22 34.9 18.1 52.0% 16.7 48.0% 
chrX 151.1 61.6 40.8% 89.4 59.2% 
chrY 25.7 9.7 37.9% 15.9 62.1% 
chrM ^ ^ 97.7% 0.0 2.3% 
Total 2858.0 1462.7 51.2% 1395.3 48.8% 
* 'N’s in the genome sequences were excluded for analysis. 
Table 4.2 The proportion of the repeat and non-repeat sequences in the human 
genome. 
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Mappable fraction of Mappable fraction of 
non-repeat region repeat region 
Chromosome 36bp 50bp 75bp 36bp 50bp 75bp 
^ 95.9% 96.4% 97.0% 77.1% 86.6% 93.6% 
chr2 96.9% 97.4% 97.9% 79.2% 87.9% 94.3% 
chr3 99.1% 99.4% 99.7% 80.3% 89.1% 95.4% 
chr4 98.5% 98.8% 99.2% 80.2% 88.6% 94.7% 
chr5 97.5% 97.9% 98.2% 78.9% 87.5% 93.8% 
chr6 98.6% 99.0% 99.3% 79.4% 88.5% 95.1% 
chr7 95.4% 96.3% 97.1% 76.1% 85.9% 93.1% 
chr8 98.0% 98.4% 98.7% 80.4% 88.9% 94.8% 
chr9 90.5% 91.2% 92.0% 71.8% 80.6% 87.3% 
chrlO 95.6% 96.1% 96.7% 77.1% 86.5% 93.2% 
chrl l 97.8% 98.4% 98.9% 79.0% 88.1% 94.7% 
chrl2 98.6% 99.0% 99.4% 78.8% 88.7% 95.7% 
chrl3 98.5% 98.9% 99.3% 82.0% 90.1% 95.8% 
chrl4 97.9% 98.3% 98.7% 78.4% 88.0% 94.8% 
chrl5 93.0% 93.9% 94.7% 75.4% 85.1% 92.2% 
chrl6 92.8% 93.6% 94.6% 73.6% 84.3% 91.8% 
chrl7 94.6% 95.6% 96.6% 71.9% 84.5% 93.9% 
chrl8 98.4% 98.8% 99.2% 81.4% 89.6% 95.5% 
chrl9 95.4% 96.8% 97.9% 70.6% 85.1% 95.3% 
chr20 98.4% 98.9% 99.3% 80.7% 89.9% 96.4% 
chr21 97.0% 97.8% 98.6% 80.1% 89.3% 95.7% 
chr22 92.2% 93.4% 94.6% 72.1% 83.8% 92.6% 
chrX 93.4% 94.0% 94.7% 75.3% 83.9% 90.2% 
chrY 47.1% 49.9% 52.8% 43.6% 50.3% 56.3% 
chrM 67.4% 76.4% 85.1% 65.7% 74.3% 85.8% 
Total 96.3% 96.8% 97.4% 77.4% 86.7% 93.4% 
Table 4.3 The percentage of mappable sequences in the repeat and non-repeat 
regions of the human genome 
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4.3.3 Allowing mismatches in the read alignment 
In the previous analysis, no mismatch was allowed in the read alignment. Here I tested 
the alignment with allowing one, or two mismatches based on the non-repeat masked 
genome. Compared with the alignment with no mismatch allowable, the uniquely aligned 
reads increased by 9.06% and 10.95% with one and two mismatches, respectively (Figure 
4.1 and Table 4.4). 
As shown in Figure 4.2 and Table 4.5, the CVs for measuring chrl3 were 1.12%, 1.13% 
and 1.13% with zero, one and two mismatches allowable, respectively. For chrl8, the 
CVs were 0.67%, 0.69% and 0.73% with zero, one and two mismatches allowable, 
respectively. CVs for measuring chrl3 and chrlS increased when more mismatches being 
allowable in the alignment. Thus, the precision of measuring chrl3 and chrl8 was worse 
when more mismatches were allowed. Therefore, no mismatch was allowed in the 
following analysis. 
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Figure 4.1 The number of uniquely aligned reads with different analysis criteria 
The boxplot of uniquely aligned reads for all the sequenced samples with different 
analysis criteria. M，repeat masked human reference genome. U, non-repeat masked 
human reference genome. 
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Index Alignment Reference Uniquely aligned reads 
mismatches mismatches genome ^ e a n SD Min Max 
0 0 Masked 2,318,545 517,888 599,711 4,213,771 
1 0 Masked 2,417,346 508,842 1,151,610 4,277,572 
1 0 Unmasked 4,568,735 964,095 2,163,261 8,098,248 
1 1 Unmasked 5,034,327 1,063,357 2,359,269 9,082,907 
1 2 Unmasked 5,137,919 1,085,926 2,400,177 9,379,106 
*Masked, repeat masked human reference genome. Unmasked, non-repeat masked 
human reference genome. 
Table 4.4 The number of uniquely aligned reads with different analysis criteria 
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Figure 4.2 The precision of quantifying autosomes with different alignment 
parameters. 
The chromosomes were ordered from left to right in increasing GC contents. 95% 
confidence interval was shown in error bars. I, number of mismatches allowable in the 
index sequence. R, number of mismatches allowable in the read alignment. M, repeat 
masked human reference genome. U, non-repeat masked human reference genome. 
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CVs (%) 
Chromosome 
lO-RQ-M Il-RO-M Il-RO-U I l -Rl-U I1-R2-U 
chr4 1.96 1.97 1.42 1.39 1.36 
chrl3 1.52 1.53 1.12 1.13 1.13 
chr5 1.05 1.05 0.8 0.79 0.78 
chr6 0.93 0.92 0.72 0.72 0.72 
chr3 0.87 0.89 0.66 0.65 0.65 
C h r i s 0 . 8 3 0 . 8 6 0 . 6 7 0 . 6 9 0 . 7 3 
chr8 0.68 0.67 0.53 0.5 0.5 
chr2 0.4 0.39 0.34 0.34 0.34 
chr7 0.5 0.48 0.43 0.41 0.41 
chrl 2 0.53 0.52 0.34 0.37 0.37 
chr21 0.62 0.6 0.55 0.54 0.55 
chrl4 0.39 0.39 0.32 0.29 0.29 
chr9 0.52 0.52 0.42 0.41 0.4 
chr l l 0.73 0.75 0.45 0.43 0.43 
chrlO 0.64 0.63 0.57 0.6 0.65 
chrl 0.67 0.67 0.52 0.51 0.51 
chrl 5 1.04 1.03 0.89 0.89 0.88 
chr20 1.87 1.89 1.53 1.5 1.48 
chrl 6 1.87 1.9 1.61 1.59 1.57 
chrl 7 2.56 2.58 2.14 2.09 2.06 
chr22 4.15 4.17 3.35 3.3 3.26 
chrl 9 ^ ^ ^ 2.72 
* I, number of mismatches allowable in the index sequence. R, number of mismatches 
allowable in the read alignment. M, repeat masked human reference genome. U, non-
repeat masked human reference genome. 
* Chromosomes were ordered from top to bottom in increasing GC contents. 
Table 4.5 CVs of quantifying autosomes with different alignment parameters 
46 
Improving the alignment 
4.3.4 The performance of trisomy 13 and 18 detection after improving the 
alignment 
After the improvement of the alignment step in the T21 bioinformatics analysis pipeline, 
the performance of the trisomy 13 and 18 was tested by calculating the z score. For 
trisomy 13, 11 of 25 trisomy 13 cases and 247 of 264 non-trisomy 13 cases were 
correctly identified, corresponding to an improved sensitivity and specificity of 44.0% 
and 93.6%, respectively (Figure 4.3). For trisomy 18, 31 of 37 trisomy 18 cases and 247 
of 252 non-trisomy 18 cases were correctly identified, corresponding to sensitivity and 
specificity of 83.8% and 98.0%, respectively (Figure 4.4). These results indicated that 
after improving the alignment step in the T21 bioinformatics analysis pipeline, the 
performance of trisomy 13 and 18 detection by NGS had been improved. However, 
compared to the trisomy 21 detection, the detection rate for trisomy 13 and 18 was still 
suboptimal. 
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Figure 4.3 Trisomy 13 detection by the T21 bioinformatics analysis pipeline with 
improved alignment 
(A) The genomic representation of chrl3 for the trisomy 13, non-trisomy 13 and control 
samples (B) The z score of chrl3 for the trisomy 13, non-trisomy 13 and control samples. 
Dashed line indicated the diagnostic cutoff with a z score value of 3. T13, trisomy 13. 
GR, genomic representation. 
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Figure 4.4 Trisomy 18 detection by the T21 bioinformatics analysis pipeline with 
improved alignment 
(A) The genomic representation of chrl8 for the trisomy 18, non-trisomy 18 and control 
samples (B) The z score of chrl8 for the trisomy 18, non-trisomy 18 and control samples. 
Dashed line indicated the diagnostic cutoff with a z score value of 3. T18, trisomy 18. 
GR, genomic representation. 
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4.4 Discussion 
In this chapter, in order to improve the alignment step in the T21 bioinformatics analysis 
pipeline, three aspects in the alignment step have been discussed, including using the 
non-repeat masked human genome instead of the repeat masked one as the alignment 
reference, allowing mismatches in the index sequences and read alignment. 
After using the non-repeat masked genome as the alignment reference, the average 
aligned reads increased by 2.2 million which was 1.9 times than that by using the repeat 
masked reference genome. All these increased reads were from the repeat regions that 
had been masked in the repeat masked genome. The simulation analysis showed that 
77.4% of the repeat regions, taking up 48.8% of the human genome, could be uniquely 
aligned with the 36 bp simulated reads. This was probably due to the fact that a large 
proportion of the repeat sequences in the human genome share certain similarity but not 
exact the same. Although these repeat elements have multiple copies in the human 
genome, but each of them are not exactly the same, which unlike the simple repeats that 
have exactly the same repeat unit. Thus those reads from such repeat regions could be 
uniquely aligned back. Therefore it was better to use the non-repeat masked human 
genome than the repeat masked one as the alignment reference. 
When the length of simulating read increased, the uniquely aligned proportion of the 
repeat region and non-repeat regions increased. Compared with simulation result with 36 
bp simulated reads, the percentage of uniquely aligned regions increased by 0.5% (50 
bp), 1.1% (75 bp) for the non-repeat sequences and 9.3% (50 bp), 16.0% (75 bp) for the 
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repeat sequences, respectively. This indicated that increasing the length of sequenced 
reads will improve the read alignment more for the repeat regions than the non-repeat 
regions. However, longer read lengths would increase the sequencing cost. Therefore a 
balance between the sequenced read length and sequencing needs to be considered. 
By allowing the mismatches in the index sequences and read alignment, the number of 
average aligned reads increased by 0.098 million, 0.47 million and 0.10 million for 1 
mismatch allowable in the index sequence, one and two mismatches allowable in the read 
alignment, respectively. However the CVs of measuring chrl 3 and chrl 8 were slightly 
worse when more mismatches were allowed in the index sequence or read alignment. 
This was due to the errors that were introduced in sorting back the reads to the samples 
and aligning the reads to the reference genome. However, unlike allowing the 
mismatches in the read alignment, allowing mismatch in the index sequences helped to 
increase the number of aligned reads of a few samples with extremely low aligned reads, 
which might be possibly due to the errors in the readout of index sequences. Therefore it 
was reasonable to allow mismatches in the index sequence but no mismatches in the read 
alignment. 
After the improvement of the alignment, the detection rate for trisomy 13 and 18 was 
44.0% and 83.8%. Although the detection rate was better than that based on the T21 
bioinformatics analysis pipeline, it was still not compatible to the detection rate for 
trisomy 21 by NGS. On the other hand, it had been observed that there was a correlation 
between the average GC content of the autosomes and the precision of quantifying the 
autosomes. The autosomes with high or low average GC content had relatively large CV. 
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This indicated that the GC content was a factor that affected the precision of quantifying 
the autosomes. This will be discussed in the following chapters. 
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CHAPTER 5: Reducing the GC bias by correction of read counts 
5.1 Introduction 
The second step of the T21 bioinformatics analysis pipeline is the quantification of 
chromosomes by counting the aligned reads in the sequencing data. 
Theoretically, if there was no bias in NGS platform, it would be expected that the 
sequenced reads from NGS platform should be uniformly distributed across the genome. 
However, it has been reported that the sequenced reads from different regions were not 
uniquely distributed (Dohm et al. 2008). The guanine and cytosine (GC) content of the 
sequenced nucleic acids has been reported to contribute to the non-uniform distribution. 
For example, it has been found that there was a positive correlation between the GC 
content and the number of sequenced reads across the genome on Illumina sequencing 
platform. There was a relatively low sequencing coverage in the GC-poor regions and 
high sequencing coverage in the GC-rich regions (Dohm et al. 2008; Harismendy et al. 
2009; Kozarewa et al. 2009). This “GC bias" was probably introduced in the PGR steps 
during the sequencing procedures (Aird et al. 2011; Harismendy et al. 2009). However, 
whether this GC bias existed in the plasma DNA sequencing data needs further 
validation. 
It is likely that this GC bias would affect the quantification of chrl3 and chrl8 by NGS in 
two aspects. First, due to GC bias, the read counts from each chromosome was not only 
correlated to the mount of sequenced DNA molecules derived from the corresponding 
chromosome, but also correlated to the GC content of that chromosome. Therefore, the 
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number of DNA molecules from each chromosome could not be precisely measured by 
the read counts from the sequencing data. Second, due to the GC content difference 
between the individual chromosome and the whole genome, the degree of the GC bias for 
individual chromosome and the whole genome was different. Therefore the proportion of 
the reads derived from certain chromosomes over the total reads from the whole genome 
(genomic representation of this chromosome) could not be precisely calculated. 
Algorithms that could reduce the GC bias in these two aspects might improve the 
performance of the trisomy 13 and 18 detection by NGS. 
In this chapter, I will check if the GC bias exists in the plasma sequencing data and 
whether this GC bias would affect the precision of quantifying chrl3 and chrl8. In order 
to reduce the GC bias, an algorithm that directly corrected the GC bias in read counts was 
developed. The performance of the trisomy 13 and 18 detection by NGS was then 
accessed after reducing the GC bias. Another algorithm that reduced the effect of GC bias 
in the calculation of genomic representation will be discussed in the next chapter. 
5.2 Methods 
5.2.1 Read alignment 
Sequenced reads were aligned to the non-repeat masked human reference genome with 
no mismatch allowable. After alignment, the reads were sorted back to the corresponding 
sample with one mismatch allowable in the index sequence. 
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5.2.2 Calculating the correlation between GC content and read counts 
The sequence of whole genome (Hgl8 NCBI.36) was first divided into consecutive 50 
kilobases (kb) segments，termed bins. The GC content of each bin was calculated by 
calculating the percentage of G+C nucleotide counts over A+T+C+G nucleotide counts. 
The ‘N，s in the genomic sequence were not considered. The reads falling in each bin 
were counted. The correlation between the GC content and the read counts in bins was 
calculated by Spearman's Rank Correlation Coefficient with R (http://www.r-
project.org). 
5.2.3 GC correction in read counts 
In order to reduce the GC bias, an algorithm was implemented to correct such bias in the 
read counts. For each sample, the whole genome sequence was first divided into 50 kb 
bins. The bin size of 50 kb was arbitrarily chosen and it will be discussed later. The 
number of aligned reads and GC content in each bin (rounded to 0.1%) were then 
calculated. Bins without any reads and bins with ‘N’ in the sequences were excluded. 
Then, the number of aligned reads in each bin against the GC content of the 
corresponding bin was fit by either linear regression or locally weighted scatterplot 
smoothing (LOESS) regression. The regression fit predicted value for each bin (P) could 
be calculated after regression by using the regression function and the GC content of each 
bin (Alkan et al. 2009). For each bin, the G C corrected read counts (RCQC) were 
calculated based on the raw read counts with the correction factor (F). The median count 
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of all bins (M) was used as the correction reference. The GC-corrected read counts were 
calculated by the following equations: 
F = M/P 
RCgC = RCraw^F 
Instead of directly using the counts of aligned read, the GC-corrected read count was then 
used to calculate the genomic representations. 
5.2.4 Trisomy 13 and 18 detection 
Trisomy 13 and 18 was detected as previously described except that z-score statistic was 
calculated by using the genomic representations derived from the GC-corrected read 
counts. 
5.3 Results 
5.3.1 GC bias in plasma DNA sequencing 
First, whether the GC bias existed in the plasma DNA sequencing data was checked. By 
calculating the correlation between the GC content and the read count with 50 kb bins, a 
positive correlation had been observed (the average correlation coefficient for all the 
samples are 0.56, SD = 0.13) (Figure 5.1). Thus the GC bias did exist in the plasma DNA 
sequencing data. 
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From previous analysis (Figure 3.3 and Figure 4.2), the chromosomes with low or high 
GC content tend to have greater variance than those with modest GC content. Thus, 
chrl3, chrl8 and chr21 with average GC content 38.52%, 39.79% and 40.88% had the 
CVs of 1.12%, 0.67% and 0.55% with improved alignment, respectively. These results 
showed that chrl3 and chrl8, which had relatively lower GC content than chr21, were 
less precisely measured. These result indicated that the GC bias affected the precision of 
measuring the GR of chromosomes, especially those chromosomes with high or low 
average GC content. Thus the GC bias needed to be reduced in order to improve the 
performance of the trisomy 13 and 18 detection by NGS. 
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Figure 5.1 The correlation between the GC contents and the read counts in the 
plasma DNA sequencing data before GC correction. 
Scatter plot of the GC contents and read counts per 50 kb bins of the plasma DNA 
sequencing data from a euploid sample before GC correction. The Spearman's Rank 
Correlation Coefficient was showed. Outliers were not plotted. 
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5.3.2 Correcting the GC bias in read counts by linear regression 
One of the possible solutions to reduce the GC bias is to directly correct such bias in read 
counts. Since there was a correlation between the GC contents and the read counts, 
eliminating this correlation would potentially reduce the GC bias and improve the 
performance for trisomy 13 and 18 detection. To test this, a GC correction algorithm with 
linear regression was implemented to eliminate the correlation. The linear regression was 
used to characterize the correlation between the GC contents and read counts in 50 kb 
bins. Theoretically, if there was no such correlation, the read counts per bin would be 
expected to be close to the median count of all bins. Therefore, the median count of all 
bins was used as the correction reference and the read counts in each bin were normalized 
to the correction reference. 
After the GC correction, the average correlation coefficient for all the samples was 0.14 
(SD = 0.018) (Figure 5.2). This indicated that the correlation between GC-corrected read 
counts and GC contents in each bin had been greatly reduced after GC correction with 
linear regression, although a slightly small correlation still existed. As shown in Table 
5.1, the CVs of measuring chrl 3 and chrl 8 decreased from 1.124% and 0.647% to 
0.426% and 0.331%, respectively, after GC correction. These results indicated that the 
precision of quantifying chrl 3 and chrl 8 by NGS had been improved by GC correction 
with the linear regression. 
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Figure 5.2 The correlation between the GC contents and the read counts in plasma 
DNA sequencing data after GC correction with linear regression. 
Scatter plot of the GC contents and read counts per 50 kb bins of the plasma DNA 
sequencing data from a euploid sample after GC correction with the linear regression. 
The Spearman's Rank Correlation Coefficient was showed. Outliers were not plotted. 
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CVs 
TvT m GC correction with Chromosome No GC correction ,. . linear regression 
chr4 1.423% 0.346% 
chrl3 1.124% 0.426% 
chr5 0.799% 0.276% 
chr6 0.723% 0.231% 
chr3 0.663% 0.266% 
Chris 0.674% 0.331% 
chr8 0.528% 0.282% 
chr2 0.338% 0.183% 
chr7 0.425% 0.269% 
chrl2 0.343% 0.326% 
chr21 0.546% 0.532% 
chrl4 0.316% 0.333% 
chr9 0.416% 0.303% 
chrl l 0.454% 0.252% 
chrlO 0.572% 0.328% 
chrl 0.519% 0.259% 
chrl5 0.895% 0.617% 
chr20 1.533% 0.366% 
chrl 6 1.614% 0.480% 
chrl 7 2.140% 0.343% 
chr22 3.355% 0.503% 
chrl 9 2.886% 1.089% 
* Chromosomes are ordered from top to bottom in increasing GC contents. 
Table 5.1 CVs of quantifying autosomes before and after GC correction with linear 
regression. 
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Next, the performance of the trisomy 13 and 18 detection after GC correction with the 
linear regression was assessed. When using the diagnostic z-score value of 3 as the 
cutoff. 22 out of 25 trisomy 13 cases and 259 out of 264 non-trisomy 13 cases were 
successfully identified (Figure 5.3). The sensitivity and specificity were thus 88.0% and 
98.1%. For trisomy 18, 34 out of 13 trisomy 37 cases and 247 out of 252 non-trisomy 18 
cases were correctly identified, corresponding to a sensitivity and specificity of 91.9% 
and 98.0% (Figure 5.4). These results indicated that the trisomy 13 and 18 detection had 
been improved by the GC correction algorithm. 
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Figure 5.3 Trisomy 13 detection after GC correction with linear regression 
The GC correction with linear regression was performed. (A) The genomic representation 
of chrl 3 after GC correction with linear regression was calculated for the trisomy 13, 
non-trisomy 13 and reference control samples (B) Z score of chrl 3 was calculated for the 
trisomy 13, non-trisomy 13 and reference control samples. Dashed line indicated the 
diagnostic cutoff with a z score value of 3. T13, trisomy 13. GR, genomic representation. 
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Figure 5.4 Trisomy 18 detection after GC correction with linear regression 
The GC correction with linear regression was performed. (A) Genomic representation of 
chrl8 after GC correction with linear regression was calculated for the trisomy 18, non-
trisomy 18 and reference control samples (B) Z score of chrl8 was calculated for the 
trisomy 18, non-trisomy 18 and reference control samples. Dashed line indicated the 
diagnostic cutoff with a z score value of 3. T18, trisomy 18. GR, genomic representation. 
64 
Reducing the GC bias by correction of read counts 
5.3.3 Correcting the GC bias in read counts by LOESS regression 
In the previous analysis, the correlation between the GC contents and read counts was 
considered as the linear relation and the linear regression was used to fit this correlation. 
However, a slightly small correlation between the GC contents and read counts still 
existed after the linear regression (average correlation is 0.14, SD = 0.018). It is possible 
that the linear regression was not good enough to fit such a correlation. Therefore, a non-
linear regression, LOESS regression, was used in the GC correction algorithm to fit this 
correlation. 
After the GC correction with LOESS regression, the average correlation coefficient for 
all the samples are 0.02 (SD = 0.004) (Figure 5.5). Compared to the results with linear 
regression, the correlation was smaller and there was almost no correlation between the 
GC contents and read counts after the GC correction with LOESS regression. 
Furthermore, the CVs of measuring chr 13 decreased to 0.31%. CVs after the GC 
correction with LOESS regression was smaller than that with linear regression (Figure 
5.6 and Table 5.2). This result indicated that the precision of quantifying chr 13 had been 
improved more by GC correction with the LOESS regression. For the precision 
measuring chr 18, the CVs slightly increased to 0.334% by 0.003%. 
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Figure 5.5 The correlation between the GC contents and the read counts in plasma 
DNA sequencing data after GC correction with LOESS regression. 
Scatter plot of the GC contents and read counts per 50 kb bins of the plasma DNA 
sequencing data from a euploid sample after GC correction with the LOESS regression. 
The Spearman's Rank Correlation Coefficient was showed. Outliers were not plotted. 
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Figure 5.6 The precision of quantifying autosomes with and without GC correction 
CVs of quantifying autosomes among control samples were plotted. CVs calculated with 
or without GC correction were plotted in different colors. The chromosomes were 
ordered from left to right in increasing GC contents. 
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CVs 
�T ^ ^ i. GC correction with GC correction with Chromosome No GC correction . t … � � . linear regression LOESS regression 
chr4 1.423% 0.346% 0.262% 
chrl3 1.124% 0.426% 0.310% 
chr5 0.799% 0.276% 0.267% 
chr6 0.723% 0.231% 0.229% 
chr3 0.663% 0.266% 0.265% 
Chris 0.674% 0.331% 0.334% 
chr8 0.528% 0.282% 0.276% 
chr2 0.338% 0.183% 0.189% 
chr7 0.425% 0.269% 0.269% 
chrl2 0.343% 0.326% 0.324% 
chr21 0.546% 0.532% 0.480% 
chrl4 0.316% 0.333% 0.334% 
chr9 0.416% 0.303% 0.295% 
chrl l 0.454% 0.252% 0.252% 
chrlO 0.572% 0.328% 0.340% 
chrl 0.519% 0.259% 0.251% 
chrl5 0.895% 0.617% 0.604% 
chr20 1.533% 0.366% 0.346% 
chrl 6 1.614% 0.480% 0.491% 
chrl 7 2.140% 0.343% 0.339% 
chr22 3.355% 0.503% 0.450% 
chrl 9 2.886% 1.089% 1.116% 
* Chromosomes are ordered from top to bottom in increasing GC contents. 
Table 5.2 CVs of quantifying autosomes before and after GC correction with linear 
regression and LOESS regression. 
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The performance of the trisomy 13 and 18 detection after GC correction with the LOESS 
regression was assessed. When using the diagnostic z-score value of 3 as the cutoff, all 
the trisomy 13 cases (25 out of 25) and 261 out of 264 non-trisomy 13 cases were 
successfully identified. The sensitivity and specificity were thus 100% and 98.9%. 
Compared with the GC correction with linear regression, the performance of the trisomy 
13 detection had been improved after the GC correction with LOESS regression. For 
trisomy 18, 34 out of 37 trisomy 18 cases and 247 out of 252 non-trisomy 18 cases were 
correctly identified, corresponding to a sensitivity and specificity of 91.9% and 98.0%. 
There was no remarkably improvement in the performance for trisomy 18 detection, 
when comparing the GC correction methods with two different regression models. 
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Figure 5.7 Trisomy 13 detection after GC correction with LOESS regression 
The GC correction with LOESS regression was performed. (A) Genomic representation 
of chrl 3 after GC correction with LOESS regression was calculated for the trisomy 13， 
non-trisomy 13 and reference control samples (B) Z score of chrl 3 was calculated for the 
trisomy 13, non-trisomy 13 and reference control samples. Dashed line indicated the 
diagnostic cutoff with a z-score of 3. T13, trisomy 13. GR, Genomic representation. 
70 







^ § 炎 




Q^  00 _ X 
J 丨 ： 
CNi ‘ ' ‘ 
Controls Non-T18 T18 
B 




0 0 ^ X 
T— 
1 s - i 
^ o - ！ 
O r X o V u W _a 1 _ _ 
� r 1 ^ 
o - g 
Y 琴 
, 1 1 
Controls Non-T18 T18 
Figure 5.8 Trisomy 18 detection after GC correction with LOESS regression 
The GC correction with LOESS regression was performed. (A) Genomic representation 
of chrl8 after GC correction with LOESS regression was calculated for the trisomy 18, 
non-trisomy 18 and reference control samples (B) Z score of chrl8 was calculated for the 
trisomy 18, non-trisomy 18 and reference control samples. Dashed line indicated the 
diagnostic cutoff with a z-score of 3. T18, trisomy 18. GR, Genomic representation. 
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5.3.4 Bin size 
In order to assess the effect of bin size in the GC correction algorithm, a series of bin size 
1 mb, 500 kb, 100 kb and 50 kb were tested. The results showed no marked difference in 
CVs among different bin sizes (Figure 5.9 and Table 5.4). However, when the bin size 
became smaller, the time for computing the LOESS regression dramatically increased. 
For example, when the bin size was 50 kb, the average time to perform the GC correction 
on one sample was longer than five hours on a computing server with an Intel(R) 
Xeon(R) CPU X5570 2.93GHz and 36G memory. In order to save the computing time, a 
500 kb bin size was used in the following analysis. 
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Figure 5.9 CVs of measuring chrl3 and chrl8 by GC correction with different bin 
sizes. 
Different bin sizes were used to perform the GC correction. M, megabases. K, kilobases. 
After GC correction, the CVs of quantifying chr 13 and chr 18 among the control samples 
were calculated. 
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CVs (%) 
Bin size (bp) 
Chr is Chrl8 
IM 0.302 0.341 
500K 0.298 0.338 
lOOK 0.302 0.333 
50K 0.310 0.334 
* M，megabases. K, kilobases. GR, genomic representation 
Table 5.3 CVs for quantifying chrl3 and chrl8 among control samples by GC 
correction with different bin size. 
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5.4 Discussion 
In this chapter, GC bias had been confirmed to exist in the plasma DNA sequencing data 
and contributed to the imprecision of quantifying chrl3 and chrl8 by NGS. In order to 
reduce such a bias, a GC correction algorithm with linear or non-linear (LOESS) 
regression had been implemented to correct such bias in read counts. After GC 
correction, the performance for trisomy 13 and 18 detection had been improved. 
The GC correction improved the precision of quantifying chrl3 and chrl8 by NGS. 
Compared with the previous results without GC correction, the CVs of quantifying chrl3 
and chrl8 decreased by up to 72.4% and 50.9%, respectively, after the GC correction. 
The detection rate also increased from 44% to 100% for trisomy 13 and 83.8% to 91.9% 
for trisomy 18. The improvement for trisomy 13 was more prominent than that for 
trisomy 18. This was probably due to the greater deviation in the average GC content for 
chrl3 (38.5%) than that for chrl8 (39.8%) compared with the average GC contents of the 
whole genome (41.7%). These results indicated that the degrees of GC bias in chrl3, 
chrl8 and whole genome were different. Moreover, the genomic representation of chrl3 
and chrl8 was calculated by using the whole genome as the reference. It was possible 
that using the chromosome with similar GC contents with chrl3 or chrl8, instead of 
whole genome, as the reference to calculate the GR of chrl3 or chrl8 might counteract 
the GC bias. This will be further discussed in the following chapter. 
Compared with the linear regression in the GC correction, the CVs of quantifying chrl3 
decreased by 27% and the detection rate for trisomy 13 increased from 88.0% to 100% by 
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using the non-linear (LOESS) regression. There was no marked difference for the 
quantification of chrl 8 or the detection of trisomy 18 by the two different regression 
models in the GC correction. Nevertheless, the overall performance of the LOESS 
regression in the GC correction was better than the linear regression. Therefore, the GC 
correction with LOESS regression will be adapted for the following analysis. 
The bin size parameter used in the GC correction algorithm was discussed in this chapter. 
By calculating the CVs of quantifying chrl 3 and chrl 8, it showed that this parameter had 
little influence on the performance of the GC correction algorithm at current sequencing 
depth. These results demonstrated that the GC correction was quite robust at current 
sequencing depth since the performance was not significantly changed with different 
parameters. However, in the current sequencing depth, the CVs of quantifying chrl 3 and 
chrl 8 were already quite low after GC correction. Therefore changing the parameters 
used in the GC correction algorithm might not significantly affect its performance. Thus, 
when applying the GC correction algorithm, one did not need to pay specifically attention 
to the parameters in the GC correction with enough sequencing depth (for example, more 
than four million reads per sample). 
Another fact needs to be considered is that the GC bias pattern might change with 
different sequencing platform and reaction reagents. For example, Illumina has updated 
its sequencing platform and also improved the sequencing reagents in order to reduce the 
GC bias. Therefore, whether the parameters used in the GC correction algorithm needs to 
be modified on different sequencing platforms and reagent versions needs to be further 
studied. 
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CHAPTER 6: Reducing the GC bias by modifying the genomic 
representation calculation 
6.1 Introduction 
In the second step of the T21 bioinformatics analysis pipeline, another part of quantifying 
chromosome was to calculate the genomic representation after counting the reads for 
each chromosome. This might be further improved. 
It has been discussed in the previous chapter that the GC bias would possibly affect the 
detection of trisomy 13 and 18 in two aspects: one is the read counts and the other is the 
genomic representation. It has been found that the degree of GC bias for chrl3, chrl 8 and 
whole genome is different due to their different average GC content. It also has been 
suspected that using the whole genome as the reference to calculate the GR of chrl 3 and 
chrl 8 might not be accurate due to the different GC effect. Using other reference 
chromosomes that have the similar GC contents with chrl3 and 18 to calculate the GC of 
these two chromosomes might counteract the GC effect. This might be another alternative 
method to reduce the GC bias effect, independently from the GC correction of read 
counts. 
In this chapter, I will test this hypothesis by modifying the genomic representation 
calculation of chrl 3 and chrl 8. The performance for trisomy 13 and 18 detection will 
also be tested after the modification. 
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6.2 Methods 
6.2.1 Modifying the genomic representation calculation 
The calculation of genomic representation of chrl3 or chrl8 was modified by calculating 
the ratio of read counts from chrl3 or chrlS over those from other chromosomes 
(reference chromosomes), instead of the whole genome. Different reference chromosome 
for chrl3 or chrl8 was tested in order to find the best one. 
6.2.2 Trisomy 13 and 18 detection 
Trisomy 13 and 18 was detected as previously described except that z-score was 
calculated by using the modified genomic representations derived from read counts 
without GC correction. 
6.2.3 Combining GC correction and modified genomic representation 
The read counts were corrected by GC correction with LOESS regression as described in 
chapter 5. The bin size was 500 kb. After the GC correction, the corrected read counts 
were used to calculate the modified genomic representation. For chrl3 and chrl8, chr4 
and chr8 were used as the reference chromosomes, respectively. CVs of quantifying 
chrl3 and chrl8 were then assessed. 
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6.3 Results 
6.3.1 Reducing the GC bias by modifying genomic representation calculation 
Since GC bias affects the precision of measuring genomic representation of chrl 3 and 
chrl 8, one possible way to reduce the GC bias is to modify the calculation of the genomic 
representation of chrl 3 and chrl 8. The original genomic representation for chrl 3 or 
chrl 8 was calculated by the read counts from chrl3 or chrl 8 over the read counts from 
all chromosomes (whole genome). However, the average GC contents of chrl 3 or chrl 8 
and whole genome are different. This difference might contribute to the imprecision of 
calculating the GR. 
To test this hypothesis, other chromosomes as reference were used to calculate the GR of 
chrl 3 and chrl 8. CVs of the original GR of chrl 3 and chrl 8 were 1.124% and 0.674%， 
respectively. When using chr4 and chr8 as the reference to calculate the modified GR for 
chrl3 and chrl 8, respectively, the CVs increased to 0.468% and 0.393%. The average 
GC contents of chrl 3 and chrl 8 were 38.5% and 39.8%. The chr4 (GC%=38.2%) and 
chr8 (GC%=40.2%) had very similar average GC contents to chrl3 and chrl8 
respectively. 
After calculating the modified genomic representation of chrl 3 and chrl 8, the standard z 
score approach was used to classify the trisomy samples. 25 out 25 trisomy 13 cases and 
261 out of 264 non-trisomy 13 cases were correctly identified, corresponding to a 
sensitivity and specificity 100% and 98.9%, respectively. For trisomy 18, 35 out of 37 
trisomy 18 cases and 247 out of 252 non-trisomy 18 cases were identified correctly, 
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corresponding to a sensitivity and specificity 94.6% and 98.0%, respectively. 
80 
Reducing the GC bias by modifying the genomic representation calculation 
A 
^ in 1 
� � o o承_ 
c 寸 
di iiilillllllll 
Total 4 5 6 3 18 8 2 7 12 21 14 9 11 10 1 15 20 16 17 22 19 
Reference chromosome 
B 
〔寸 - 1 1 
I S - I 
《llliiiiiilllllllllll 
Total 4 13 5 6 3 8 2 7 12 21 14 9 11 10 1 15 20 16 17 22 19 
Reference chromosome 
Figure 6.1 CVs of quantifying chrl3 and chrl8 by using different reference 
chromosomes. 
CVs of modified GR of (A) chrl3 and (B) chrl8 by using different reference 
chromosomes. Total, total chromosomes (whole genome). 
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Reference chr Average GC CVs of CVs of 
contents (%) chrl3/reference chr (%) chrl8/reference chr (%) 
chr4 38.218 0.468 0.914 
chr13 38.520 - 0.659 
chr5 39.519 0.474 0.432 
chr6 39.600 0.596 0.468 
chr3 39.691 0.606 0.433 
chr 18 39.785 0.659 -
chr8 40.167 0.729 0.393 
chr2 40.236 0.862 0.482 
chr7 40.738 0.881 0.490 
chrl2 40.804 1.013 0.636 
chr21 40.878 1.459 1.001 
chrl4 40.887 1.108 0.699 
chr9 41.317 1.437 0.977 
chr l l 41.566 1.498 1.048 
chr 10 41.585 1.613 1.134 
chrl 41.743 1.595 1.136 
chr 15 42.205 1.823 1.431 
chr20 44.126 2.630 2.153 
chr16 44.789 2.682 2.213 
chr17 45.531 3.226 2.776 
chr22 47.983 4.450 3.987 
chr 19 48 364 3.913 3.496 
Whole genome 41.679 L m 0.674 
*The chromosomes were ordered by their average GC contents from high GC contents to 
low. 
Table 6.1 CVs of modified GR of chrl3 and chrl8 by using different reference 
chromosomes. 
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Figure 6.2 Trisomy 13 detection by using modified genomic representation 
calculation 
(A) Modified genomic representation of chrl 3 was calculated for the trisomy 13, non-
trisomy 13 and reference control samples. Chr4 was used as the reference chromosome to 
calculate the GR of chrl 3 (B) The z score of chrl 3 by using the modified genomic 
representation was calculated for the trisomy 13, non-trisomy 13 and reference control 
samples. Dashed line indicated the diagnostic cutoff with a z-score of 3. T13, trisomy 13. 
GR, genomic representation. 
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Figure 6.3 Trisomy 18 detection by using modified genomic representation 
calculation 
((A) Modified genomic representation of chrl 8 was calculated for the trisomy 18, non-
trisomy 18 and reference control samples. Chr8 was used as the reference chromosome to 
calculate the GR of chrl 8 (B) The z score of chrl 8 by using the modified genomic 
representation was calculated for the trisomy 18, non-trisomy 18 and reference control 
samples. Dashed line indicated the diagnostic cutoff with a z-score of 3. T18, trisomy 18. 
GR, genomic representation. 
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6.3.2 Combining GC correction and modified genomic representation 
Two independent methods, GC correction and modified genomic representation, had 
been developed to reduce the GC bias in the sequencing data. Both of these two methods 
had greatly improved the detection accuracy for trisomy 13 and 18. However, these two 
methods were independently used in the analysis pipeline. One might suspect that by 
combining these two methods, the GC bias could be further reduced. Nevertheless, 
whether this hypothesis was substantiated was unclear. Here, I combined these two GC 
bias reduction methods and assessed the performance. 
After combining the two GC bias reduction methods, the CVs of quantifying chr 13 and 
chr 18 were 0.371% and 0.384%, respectively. The precision of quantifying chr 13 and 
chr 18 by combining these two methods were worse than that by GC correction, but better 
than that by modified genomic representation. These results indicated that the 
performance of combining these two methods was no better than that of GC correction 
alone. 
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Figure 6.4 The precision of quantifying chrl3 and chrl8 by different GC bias 
reduction methods. 
CVs of quantifying chrl3 and chrl8 by GC correction, modified genomic representation 
or combining these two methods. 
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CVs (%) 
chr21 chrl8 
GC correction 0.31% 0.33% 
Modified genomic representation 0.47% 0.39% 
Combined 0.37% 0.38% 
Table 6.2 CVs of quantifying chrl3 and chrl8 by different GC bias reduction 
methods. 
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6.4 Discussion 
In this chapter, another independent method was developed to reduce the GC bias in the 
genomic representation calculation, besides the GC correction. Chr4 and chr8 were used 
as the reference chromosomes for chrl3 and chrl8, respectively, to calculate the modified 
genomic representation. Compared with the results using original genomic representation 
calculation, the CVs for quantifying chrlSand chrl8 increased from 1.12% to 0.47% and 
0.67% to 0.39%, respectively. CVs for quantifying chrl3 and chrl8 had been improved 
by 58.2% and 41.3%, respectively. The detection rate increased from 44.0% to 100% for 
trisomy 13 and 83.8% to 98.0% for trisomy 18. 
Comparing GC correction method and modified GR method, the CVs for quantify chrl3 
were 0.310% and 0.468%, respectively. For chrl8, the CVs were 0.334% and 0.393%. 
These results indicated that the GC correction method outperformed the modified GR 
method. However, the performance for trisomy 13 and 18 detection based on these two 
GC bias reducing method were similar in current sequencing depth. Both of the methods 
greatly improved the precision of measuring chrl3 and chrl8 and also improved the 
performance for trisomy 13 and 18 detection. Nevertheless, it would be expected when 
the sequencing depth was low, the GC correction method would have a better 
performance than the modified GR method. 
The GC correction method and modified GR method were independently used to reduce 
the GC bias. Whether these two methods could be combined to reduce the GC bias is 
unclear. Therefore, the two independent GC bias reduction methods have been combined 
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and tested. The results showed that the precision of quantifying chrl3 and chrl8 by 
combining these two methods was worse than that by GC correction alone, but better than 
that by modified genomic representation alone. Although these two methods reduced the 
GC bias in two different aspects independently, one in the read counts, the other in the 
genomic representation calculation, the performance of combining these two methods 
was suboptimal. This was probably because that after GC correction, the pattern of GC 
bias was different for chrl3 and chr4 or chrl8 and chr8. Therefore using chr4 and chr8 as 
the reference to calculate the modified genomic representation for chrl3 and chrl8 was 
not appropriate. Since the GC correction was the best method for reducing the GC bias, it 
will be adapted for the following analysis. 
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CHAPTER 7: Improving the statistics for trisomy 13 and 18 
detection 
7.1 Introduction 
The third part could be further improved in the T21 analysis pipeline is the statistics for 
trisomy 13 and 18 detection. In the previous analysis, the z score approach was used to 
determine the trisomy status by comparing the test samples with the control samples 
(euploid samples). Therefore, this statistical method needs several control samples to be 
sequenced. In this study, four euploid samples were sequenced in each sequencing run 
and a total of 103 euploid cases were sequenced as the control samples (13 of them have 
been sequenced twice in different sequencing runs). This approach markedly increased 
the sequencing cost for trisomy 13 and 18 diagnosis. 
However, except for the trisomic chromosome, the remaining chromosomes are normal in 
the genome of a trisomy fetus. Therefore, instead of comparing the test sample with 
normal samples, one could compare the test chromosome with the normal chromosomes 
within one sample to determine the trisomy status of the test sample. 
In this chapter, I will develop new statistical procedure to determine the trisomy status by 
comparing the test chromosome with other chromosomes or regions. The performance of 
the new statistical procedure will be assessed. 
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7.2 Methods 
7.2.1 Comparing chrl3 or chrl8 with other chromosomes within the sample 
Instead of comparing the test sample with the control samples by the z score approach, 
the trisomy status will be determined by comparing the test chromosome, e.g. chrl3 or 
chrl 8, with the other chromosome within the sample. To achieve this, the sequenced 
reads were analyzed as previously described. The genome was divided into 500 kb 
consecutive bins. The GC correction with LOESS regression was used to reduce the GC 
bias in the read counts. After GC correction, the GC-corrected read counts from chrl3 or 
chrl 8 were compared with other chromosomes by Wilcoxon Rank Sum test. The 
chromosome 21, X and Y were excluded for comparison. The p value cutoff 0.05 was 
used to determine the trisomy status. Since no control samples were needed in this 
analysis, all the control samples in the previous analysis were used as the test samples. 
7.2.2 Comparing chrl3 or chrl8 with the artificial chromosomes 
Two artificial chromosomes were constructed for comparison reference. One was for 
chrl3, termed artificial chrl3, the other was for chrl8, termed artificial chrl8. The 
artificial chromosome was constructed as following. The whole genome was divided into 
500 kb bins. For each of the bin in chrl 3, three bins from other chromosomes (autosomes 
except chrl3, chrl8 and chr21) were chosen. These three bins must have the same GC 
contents and mappability as the corresponding bin in chrl3. Therefore each bin in chrl3 
was corresponded to three bins in the artificial chrl3. The artificial chrl3 was constructed 
by combined all the bins that have same GC contents and mappability as the bins in 
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chrl3. The artificial chrl 8 was constructed in the same way. The GC correction with 
LOESS regression was used to reduce the GC bias in the read counts. After GC 
correction, the GC-corrected read counts from chrl3 or chrl8 were compared with that 
from the artificial chrl3 and chl8 by Wilcoxon Rank Sum test. The p value cutoff 0.05 
was used to determine the trisomy status. Since no control samples were needed in this 
analysis, all the control samples in the previous analysis were used as the test samples. 
7.3 Results 
7.3.1 Determining the trisomy 13 and 18 status by comparing chromosomes within 
the samples 
Instead of comparing chrl 3 or chrl 8 among samples by the z score approach, the trisomy 
13 and 18 status was determined by comparing chrl3 or chrl8 with other chromosomes 
within the sample. After the GC correction, the p value for each sample by the Wilcoxon 
Rank Sum test was calculated (Figure 7.1). By using the p value cutoff 0.05, 25 out 25 
trisomy 13 cases and 246 out of 264 non-trisomy 13 cases were correctly identified, 
corresponding to a sensitivity and specificity 100% and 93.2%, respectively. For trisomy 
18, 37 out of 37 trisomy 18 cases but no non-trisomy 18 cases were identified correctly, 
corresponding to a sensitivity and specificity 100% and 0%, respectively. 
In Figure 7.1, it is showed that the trisomy cases have smaller p values than the non-
trisomy cases. These results indicated that it was feasible to compare the chromosomes 
within the sample to determine the trisomy status. However, by using a fix cutoff (p value 
=0.05), the performances for trisomy 13 and 18 detection were markedly different. 
93 
Improving the statistics for trisomy 13 and 18 detection 
To examine the reason, the read counts distribution for chr 13, 18 and other autosomes 
(except chr21) from a euploid sample was plotted after GC correction (Figure 7.2). It has 
been observed that the median read counts per 500 kb bin of chr 13 and chr 18 was higher 
than those of autosomes (except chr21) in the euploid sample. Therefore, if one compared 
chr 13 and 18 with the autosomes (except chr21) to determine the trisomy 13 and 18 
status, this would cause a relatively high false positive rate. 
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Figure 7.1 Trisomy 13 and 18 detection by comparing chrl3 or chrl8 with other 
chromosomes 
The whole genome was divided into 500 kb bins and the number of read counts for each 
bin was calculated. The read counts from chrl3 or chrl8 were compared with those from 
other chromosomes by the Wilcoxon Rank Sum test. The p value was plotted for (A) 
trisomy 13 and (B) trisomy 18 detection. Since no control samples were needed, those 
control samples in the previous analysis were test samples in this analysis. Dashed line 
indicated the diagnostic cutoff with p value of 0.05. T13, trisomy 13. T18, trisomy 18. 
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Figure 7.2 The distribution of read counts per 500 kb for chrl3,18 and other 
autosomes except chr21 after GC correction. 
The boxplot of read counts per 500kb bin from a euploid sample. The median read counts 
per bin from chr 13 and chrl 8 is higher than those from other autosomes (except chr21). 
This trend was also observed in other euploid samples. Dashed line indicated the median 
read counts per bin of the other autosomes (except chr21). 
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7.3.2 Determining the trisomy 13 and 18 status by comparing chrl3 or chrl8 with 
artificial chromosomes. 
Theoretically, if there is no bias in the NGS data, the read counts distribution should be 
similar across different chromosomes in the euploid sample. However, it has been 
observed that this is not the case. This is probably due to two factors result in the 
different read counts different among chromosomes. One major factor is the mappability 
of different chromosomes. Since only the uniquely aligned reads were retained for 
analysis, regions with different mappability might have different uniquely aligned reads. 
A weak correlation between the read counts and the mappability was observed 
(Spearman's rank correlation coefficient = 0.257). The other factor is the remaining GC 
bias in read counts after GC correction. It would be expected that using the 
"chromosomes" with similar GC and mappability as the comparison references to chrl3 
and chrl8 would counteract this affect. 
In order to address this problem, two artificial chromosomes that have the similar GC 
contents and mappability to chrl3 and chrl8 had been constructed, called artificial chrl3 
and artificial chrl8, respectively. By using the artificial chromosomes as the comparison 
references and a fixed p value cutoff of 0.05, 25 out 25 trisomy 13 cases and 260 out of 
264 non-trisomy 13 cases were correctly identified, corresponding to a sensitivity and 
specificity 100% and 98.5%, respectively. Since no control samples were needed in this 
analysis, the previous euploid control samples used in the z score approach were also 
considered as the test samples. All the euploid "control" samples were correctly 
identified, resulting in a final specificity of 98.9%. For trisomy 18, 35 out of 37 trisomy 
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18 cases and 251 out of 252 non-trisomy 18 cases were identified correctly, 
corresponding to a sensitivity and specificity 94.6% and 99.6%, respectively. All the 
euploid "control" samples were correctly identified, resulting in a final specificity of 
99.7%. 
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Figure 7.3 Trisomy 13 and 18 detection by comparing chrl3 or chrl8 with artiHcial 
chromosomes 
Two artificial chromosomes with the similar GC contents and mappability to chrl3 and 
chrl 8 were constructed, respectively. The read counts from chrl3 or chrl8 were 
compared with those from artificial chromosomes by the Wilcoxon Rank Sum test. The p 
value was plotted for (A) trisomy 13 and (B) trisomy 18 detection. Since no control 
samples were needed, those control samples in the previous analysis were test samples in 
this analysis. Dashed line indicated the diagnostic cutoff with p value of 0.05. T13, 
trisomy 13. T18, trisomy 18. 
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7.4Discussion 
In this chapter, the third step of the T21 bioinformatics analysis pipeline, the statistics for 
trisomy 13 and 18 detection, had been improved. A new statistics that compared chr 13 or 
chr 18 with the artificial chr 13 or chr 18 had been developed. In this new trisomy detection 
method, no controls samples were needed. Therefore, the sequencing cost for trisomy 13 
and 18 detection could be reduced. Compared with the z score approach, the performance 
of the trisomy 13 and 18 detection had further improved by new statistics. 
After the GC correction, the bias of read counts for different chromosomes still existed. 
Compared with the chr21, the chr 18 and chr 13 were over represented even in a euploid 
sample by calculating the GC-corrected read counts. These results indicated that the bias 
still existed and thus the read counts from different chromosomes could not be compared 
directly. Fan et al. also developed an algorithm to detect the trisomy 13 and 18 by 
comparing the chromosomes within the sample (Fan et al. 2010). They calculated a "base 
line" to correct such bias across different chromosomes within the same sample. 
However, the “base line" was calculated based on the trisomy samples. In other words, 
the control trisomy samples were needed. However, in my algorithm, the artificial 
chromosomes were constructed to correct the bias and most importantly, no control 
samples were needed. Therefore, my algorithm is the really "control sample free" 
algorithm to detect the trisomy 13 and 18. 
After the improvement in the three steps of the T21 bioinformatics analysis pipeline, the 
performance of the trisomy 13 and 18 detection had been greatly improved and was also 
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compatible to that for trisomy 21 detection. Most importantly, all the improvement were 
only made in the bioinformatics aspects. Those modifications to the analysis pipeline 
would not increase the cost of the trisomy 13 and 18 detection by NGS. 
101 
SECTION V ： CONCLUDING REMARKS 
102 
Conclusion and future perspectives 
CHAPTER 8: Conclusion and future perspectives 
8.1 The performance of the T21 bioinformatics analysis pipeline developed for 
trisomy 21 detection is suboptimal for trisomy 13 and 18 detection 
The NGS technologies, combined with the knowledge of cell free fetal DNA in the 
plasma of pregnant women, have been demonstrated to be feasible to detect the trisomy 
21 noninvasively. Recently, two large scale studies based on NGS from our group and 
other group reported a sensitivity of 100% and specificity of 97.9% to 99.7% respectively 
on trisomy 21 detection (Chiu et al. 2011; Ehrich et al. 2011). Detection of trisomy 13 
and 18 noninvasively is also an important clinical application for NGS. Therefore, in this 
thesis, efforts have been made to evaluate the performance for trisomy 13 and 18 by NGS 
in a noninvasive way. Recently, two studies that investigated the NGS application for 
trisomy 13 or 18 detection has also been published (Fan et al. 2010; Sehnert et al. 2011). 
As demonstrated in Chapter 3, the performance for trisomy 13 and 18 detection by NGS 
is suboptimal. By using the bioinformatics analysis pipeline originally designed for 
trisomy 21 detection, it could only identify 36.0% and 73.0% of trisomy 13 and 18 at 
specificities of 92.4% and 97.2%, respectively. The performance for trisomy 13 and 18 
detection is not compatible with that on trisomy 21 detection by NGS. Furthermore, the 
precision of quantifying chrl 3 and chr 18 is worse than that of chr21. Therefore, I 
attempted to modify the bioinformatics analysis pipeline in order to improve the 
diagnostic performance for trisomy 13 and 18 detection. Improvement in three aspects 
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including read alignment, quantification of chromosomes and statistics for trisomy 
detection has been made. 
8.2 The alignment could be improved by allowing one mismatch in the index and 
using the non-repeat masked human reference genome as the alignment reference 
The first step in the T21 bioinformatics analysis pipeline is the read alignment. By 
allowing one mismatch in the index and using the non-repeat masked human reference 
genome as the alignment reference, the read counts per sample had dramatically 
increased. Moreover, the precision of quantifying chrl3 and chrl8 had also been 
improved. After such improvement in the read alignment, 11 of 25 trisomy 13 cases and 
247 of 264 non-trisomy 13 cases were correctly identified, corresponding to an improved 
sensitivity and specificity of 44.0% and 93.6%, respectively. For trisomy 18, 31 of 37 
trisomy 18 cases and 247 of 252 non-trisomy 18 cases were correctly identified, 
corresponding to a sensitivity and specificity of 83.8% and 98.0%, respectively. 
However, although the performance of the trisomy 13 and 18 detection was improved, the 
detection rate for trisomy 13 and 18 was still suboptimal. 
8.3 The precision of quantifying chrl3 and chrl8 could be improved by the GC 
correction or the modified genomic representation 
The second step in the T21 bioinformatics analysis pipeline is the quantification of 
chromosomes by NGS. The GC content bias had been found to affect the precision of 
quantifying chrl3 and chrl8. Two independent methods had been developed to reduce 
such GC content bias. One was the GC correction with LOESS regression, the other was 
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the modified genomic representation. Both of the GC bias reduction methods greatly 
improved the precision of quantifying chrl 3 and chrl 8, and also improved the trisomy 13 
and 18 detection. It showed that the GC correction method outperformed the modified 
genomic representation method in improving the precision of quantifying chrl 3 and 
chrl8. Combining these two GC bias reduction methods did not outperform the GC 
correction method alone. By using the GC correction, 25 out 25 trisomy 13 cases and 261 
out of 264 non-trisomy 13 cases were correctly identified, corresponding to a sensitivity 
and specificity 100% and 98.9%, respectively. For trisomy 18, 35 out of 37 trisomy 18 
cases and 247 out of 252 non-trisomy 18 cases were identified correctly, corresponding to 
the sensitivity 94.6% and specificity 98.0%, respectively. 
8.4 The statistics for trisomy 13 and 18 detection could be improved by 
comparing chrl3 or chrl8 with artificial chromosomes within the sample 
The third step in the T21 bioinformatics analysis pipeline is the calculation of the z score 
for trisomy 13 and 18 detection. However, by calculating the z score, several control 
samples were needed to calculate the distribution of the GR of chrl 3 and chrl 8 in euploid 
samples (four control samples in each sequencing run were designed in this study). This 
would cost more for sequencing these control samples. Therefore, a new statistics that 
compared chrl3 or chrl8 with the artificial chromosomes derived from the autosomes 
within the same sample had been developed. After adapting the new statistical approach, 
25 out 25 trisomy 13 cases and 260 out of 264 non-trisomy 13 cases were correctly 
identified, corresponding to the sensitivity and specificity 100% and 98.5%, respectively. 
Since no control samples were needed in this analysis, the previous euploid control 
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samples used in the z score approach were also considered as the test samples. All the 
euploid "control" samples were correctly identified, resulting in a final specificity of 
98.9%. For trisomy 18, 35 out of 37 trisomy 18 cases and 251 out of 252 non-trisomy 18 
cases were identified correctly, corresponding to the sensitivity and specificity 94.6% and 
99.6%, respectively. All the euploid "control" samples were correctly identified, resulting 
in a final specificity of 99.7%. Besides no control samples were needed, the performance 
for trisomy 13 and 18 detection by the new statistical method was better than that by the z 
score approach. 
After the improvement in these three aspects, the performance of the trisomy 13 and 18 
by the improved bioinformatics analysis pipeline is now compatible to the performance 
of the trisomy 21 detection. 
8.5 Prospects for future work 
Consider the fetal DNA concentration information on the trisomy 13 and 18 detection 
Theoretically, the higher the fetal DNA concentration is, the easier to detect fetal DNA 
molecules by NGS. Therefore overrepresentation of the trisomic chromosome would be 
more difficult to detect when the fetal DNA concentration is low and vice versa. The 
small overrepresentation of trisomic chromosome detected in the low fetal DNA 
concentration is more significant than that in the high concentration. One could give 
weights to the p value calculated by the improved bioinformatics analysis pipeline so that 
the trisomy and non-trisomy samples could be more precisely and confidently identified. 
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Trisomy 13 and 18 detection by the target sequencing technology 
In this study, the whole genome of each sample was sequenced. However, in the 
improved bioinformatics analysis pipeline, only subsets of the genomic regions were 
needed to detect the trisomy 13 and 18. For example, only the regions in chrl3 or chrl8 
and artificial chrl3 or artificial chrl8 were needed to be sequenced. Therefore, by using 
the new bioinformatics analysis pipeline, one could only sequence the regions that used 
in this pipeline by target sequencing technology, which has been used to detect the fetal 
alleles from maternal plasma DNA (Liao et al. 2011). By using sequencing technology, 
one could obtain hundreds of times more reads in specific regions. This will increase the 
detection power of the improved bioinformatics analysis pipeline and also save the 
sequencing cost. However, the pattern of the GC bias might change by using the target 
sequencing technology. Thus, further study might be needed to test the analysis pipeline 
on the data from target sequencing. 
Implementing the new analysis pipeline into an easy-to-use software 
Currently, the new analysis pipeline was implemented in Python and R programming 
language. Only persons with specific bioinformatics background could properly use this 
pipeline to analyze the sequencing data. It might be difficult or even impossible for the 
doctors and people who do not have specific bioinformatics background to perform the 
analysis. Therefore, it is worthy to implement the new analysis pipeline into an easy-to-
use software. The new analysis pipeline could be implemented into a standalone 
executable Java application or a web based analysis application. 
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